The class action centers on accusations that ADMA Biologics and its leadership engaged in securities fraud. The scrutiny intensified on March 24, 2026, when Culper Research released a report characterizing the company’s reported growth as a fiction. The researchers alleged that ADMA utilized a de facto channel stuffing scheme and an undisclosed related-party distributor to mask a 3% revenue decline as 20% growth. Following the release, ADMA shares dropped 16.63% to close at $11.33.
ADMA Biologics Faces Class Action Lawsuit Following Fraud Allegations
Investors who purchased ADMA Biologics securities during the designated class period now have until August 10, 2026, to seek appointment as lead plaintiff. The legal action follows a series of sharp stock price declines triggered by allegations of artificial revenue inflation through undisclosed distribution schemes.
Market confidence eroded further on March 26, 2026, after Cantor Fitzgerald downgraded the stock. Analysts cited the company’s inadequate response to the specific claims leveled by Culper Research, leading to an additional 13.91% decline in share price to $8.29. Investors seeking to participate in the litigation led by Pomerantz LLP are instructed to contact Danielle Peyton at 646-581-9980 or via email at dpeyton@pomlaw.com.
Comments (0)
No comments yet. Be the first!